You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 6,130,248


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 6,130,248
Title: Tricarboxylic acid-containing oxyalkyl esters and uses thereof
Abstract:This invention relates to compositions for and methods of treating, preventing or ameliorating cancer and other proliferative diseases as well as methods of inducing wound healing, treating cutaneous ulcers, treating gastrointestinal disorders, treating blood disorders such as anemias, immunomodulation, enhancing recombinant gene expression, treating insulin-dependent patients, treating cystic fibrosis patients, inhibiting telomerase activity, treating virus-associated tumors, especially EBV-associated tumors, augmenting expression of a tumor suppressor gene and inducing tolerance to an antigen. The methods of the invention use tricarboxylic acid substituted oxyalkyl esters.
Inventor(s): Nudelman; Abraham (Rehovot, IL), Rephaeli; Ada (North Caldwell, NJ)
Assignee: Bar-ILAn University (Ramat-Gan, IL) Mor Research Applications, Ltd. (Givat Shmuel, IL) Beacon Laboratories, Inc. (Phoenix, MD)
Application Number:08/781,905
Patent Claims:1. A compound represented by the formula: ##STR19## wherein R is n-propyl, isopropyl, 1-methylpropyl, n-butyl, isobutyl, 1-methylbutyl, 2-methylbutyl, n-amyl, isoamyl, 1-, 2-, or 3-methylamyl, 2-ethylbutyl or benzyl, any of which can be optionally substituted with halo, trifluoromethyl, amino, alkoxy or aryl; or R is C.sub.3 to C.sub.5 linear alkenyl, optionally substituted with halo, trifluoromethyl, amino, alkoxy or aryl;

R.sup.1 and R.sup.2 are independently H, lower alkyl or lower alkenyl;

A is arylene or C.sub.1 to C.sub.8 alkylene, alkenylene or alkynylene, wherein alkylene, alkenylene and alkynylene are optionally substituted with one or more of hydroxy, halo, lower alkyl, alkoxy, carbonyl, thiol, lower alkylthio or aryl;

R.sup.3 is H, lower alkyl, aryl, or --CR.sup.1 R.sup.2 --O--C(O)--R; or

a pharmaceutically-acceptable salt thereof.

2. The compound of claim 1, wherein

R is n-propyl, 3-(phenyl)propyl, 2-propenyl or benzyl;

A is arylene or C.sub.1 to C.sub.8 alkylene, alkenylene or alkynylene, wherein alkylene, alkenylene and alkynylene are optionally substituted with one or more of hydroxy, halo, lower alkyl, alkoxy, carbonyl, thiol, lower alkylthio or aryl;

R.sup.3 is H, lower alkyl, or --CR.sup.1 R.sup.2 --O--C(O)--R; or

a pharmaceutically-acceptable salt thereof.

3. The compound of claim 1, wherein said compound is mono-(butyroyloxymethyl)glutarate, bis-(butyroyloxymethyl)glutarate, mono-(1-butyroyloxyethyl)glutarate, or bis-(1-butyroyloxyethyl)glutarate.

4. A pharmaceutical composition comprising a therapeutically-effective amount of a compound of any one of claims 1 to 3 and a pharmaceutically-effective carrier or diluent.

5. A pharmaceutical composition comprising a therapeutically-effective amount of a compound of any one of claims 1 to 3 with a therapeutically-effective amount of a pharmaceutical agent, wherein said agent is selected from the group consisting of a cytokine, an interleukin, an anti-cancer agent or anti-neoplastic agent, a chemotherapeutic agent, an antibody, a conjugated antibody, an immune stimulant, an antibiotic, a hormone antagonist or a growth stimulant.

6. The composition of claim 5 wherein said pharmaceutical agent comprises a cytotoxic agent.

7. The composition of claim 5 wherein said antibiotic is an antiviral nucleoside antibiotic selected from the group consisting of ganciclovir, acyclovir, and famciclovir.

8. The composition of claim 5 wherein said antibiotic is ganciclovir.

9. The composition of claim 5 wherein said chemotherapeutic agent is selected from the group consisting of alkylating agents, purine and pyrimidine analogs, vinca and vinca-like alkaloids, etopsides and etopside-like drugs, corticosteroids, nitrosoureas, antimetabolites, platinum based cytotoxic drugs, hormonal antagonists, anti-androgens and antiestrogens.

10. The composition of claim 5, wherein said cytokine is an interferon.

11. The composition of claim 5, wherein said immune stimulant is Corynebacterium parvum or a sarcolectin.

12. The composition of claim 5, wherein the chemotherapeutic agent is selected from the group consisting of tamoxifen, doxorubicin, 1-asparaginase, decarbazine, amacrine, procarbazine, hexamethylmelamine, mitosantrone and gemcitabine.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.